A randomised clinical trial of treatment for fluorouracil-resistant advanced colorectal cancer comparing standard single-agent irinotecan versus irinotecan plus panitumumab and versus irinotecan plus ...

Mise à jour : Il y a 5 ans
Référence : EUCTR2005-003492-20

A randomised clinical trial of treatment for fluorouracil-resistant advanced colorectal cancer comparing standard single-agent irinotecan versus irinotecan plus panitumumab and versus irinotecan plus ciclosporin

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The PICCOLO Trial has two separate objectives. Firstly, to establish whether the toxicity of irinotecan (Ir) therapy is reduced, without loss of efficacy, by modulation with ciclosporin (Cs). Secondly, to establish whether, in patients with K-RAS wild-type tumours not previously treated with anti-EGFR therapy, the efficacy of Ir therapy is improved by the addition of panitumumab (Pan).


Critère d'inclusion

  • Fluorouracil-resistant advanced colorectal cancer